Skip to content

Study on the Efficacy of Comprehensive Circadian Rhythm Regulation Based on Artificial Intelligence Algorithms and an App in Patients with Delayed Sleep-Wake Phase Disorder

Study on the Efficacy of Comprehensive Circadian Rhythm Regulation Based on Artificial Intelligence Algorithms and an App in Patients with Delayed Sleep-Wake Phase Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120542
Enrollment
Unknown
Registered
2026-03-16
Start date
2026-03-16
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delayed Sleep-Wake Phase Disorder

Interventions

Experimental Group 1:Digital comprehensive rhythm regulation under the guidance of physicians
Experimental Group 2:Artificial intelligence-driven individualized integrated rhythm regulation
Control Group:None

Sponsors

The Affilated Brain Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as DSWPD according to the diagnostic criteria of ICSD-3; 2. Age range 15-30, gender not restricted; 3. Proficient in using the digital platform specified in this study and able to complete all assessments.

Exclusion criteria

Exclusion criteria: 1. Merge other mental comorbidities that meet the DSM-5 diagnostic criteria, including bipolar disorder, schizophrenia, attention deficit and hyperactivity disorder, etc.; 2. Have taken sedative-hypnotic drugs or exogenous melatonin or other drugs that may affect the circadian rhythm within the past three months; 3. Have concurrent organic brain diseases, history of brain trauma or other major physical diseases; 4. Have engaged in self-harm or suicidal behavior in the past three months; 5. Have eye diseases such as glaucoma, retinal diseases, macular degeneration, or are taking known photosensitive drugs; 6. Participants currently participating in other interventional clinical studies; 7. The individual or their legal guardian refuses to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Actigraphy-measured daily sleep onset and wake times;

Secondary

MeasureTime frame
Chronotype;Severity of Insomnia;Severity of depressive symptoms;Severity of anxious symptoms;Suicidal ideation;

Countries

China

Contacts

Public ContactJihui Zhang

The Affilated Brain Hospital of Guangzhou Medical University

zhangjihui@gzhmu.edu.cn+86 198 0209 9630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026